Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma

Although checkpoint molecules like CTLA-4 and PD1 have been described several years ago, checkpoint inhibitors such as Nivolumab (an anti-PD-1 antibody) have only recently been used to treat classic Hodgkin lymphoma (cHL). Several studies have shown convincing therapeutic effects of Nivolumab in cH...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Kübra Yadigaroglu, Sonja Scharf, Steffen Gretser, Hendrik Schäfer, Aresu Sadeghi Shoreh Deli, Andreas G. Loth, Hasmik Yegoryan, Roland Schmitz, Emmanuel Donnadieu, Martin-Leo Hansmann, Sylvia Hartmann
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Ferrata Storti Foundation 2024-05-01
Schriftenreihe:	Haematologica
Online-Zugang:	https://haematologica.org/article/view/11608
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!